Nanobiotix Combination of firstinclass NBTXR3 radiotherapy and antiPD1 immunotherapy demonstrate efficacy in treating resistant preclinical in vivo models of lung cancer

Nanobiotix: Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer

Data presented at AACR Annual Meeting 2019 In vivo study conducted alone or in collaboration with The University of Texas MD Anderson Cancer Center demonstrated: NBTXR3 in combination with a PD-1 ...

More From BioPortfolio on "Nanobiotix: Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer"